Get notified of page updates
Enroll in Research > Research Search & Enroll Tool > PATROL Study: Prostate Cancer Screening for People AT Genetic Risk FOr Aggressive Disease
Glossary on
off
Printer Friendly Page PATROL Study: Prostate Cancer Screening for People AT Genetic Risk FOr Aggressive Disease

PATROL Study: Prostate Cancer Screening for People AT Genetic Risk FOr Aggressive Disease

Clinicaltrials.gov identifier:
NCT04472338

Prevention
Screening study for people with a mutation linked to prostate cancer risk

Study Contact Information:

Contact patrol@uw.edu or by phone at 206-210-4040.


PATROL Study: Prostate Cancer Screening for People AT Genetic Risk FOr Aggressive Disease

About the Study

The PATROL ( Cancer Screening for People AT Genetic Risk FOr Aggressive Disease) study is for people at risk for cancer because they carry one or more genes that are known or suspected to increase cancer risk: , , , , , , , , , , , or .

This is a good study for people who wish to be proactive about their care and contribute to studying new ways of monitoring for cancer risk, including studying new markers for finding cancer early. Participation involves study visits approximately once a year with physical exam, blood tests (including ) and urine test. Biopsies and imaging may be advised based on exam and blood test results. There are also patient questionnaires. Contact patrol@uw.edu or go to http://sites.uw.edu/patrolstudy for more information.

What the Study Involves

The PATROL study is an early-detection screening study. Study procedures include annual clinic visit, ( Specific Antigen) blood test, and imaging as deemed necessary by your doctor. A biopsy may be recommended based on age and if you are:

  • under 50, with a over 1.0 ng/mL
  • between 50 and 59 with a over 1.5 ng/mL
  • over 60 with a over 2.0 ng/mL

At each annual PATROL visit, participants will be asked to fill out a survey, and blood and urine samples will be collected for the PATROL biorepository. The annual visits and collections will be conducted for 10 years after enrollment. For people who are diagnosed with cancer during the study, the medical care plan will be determined by the patient’s urologist and medical team.

Study Locations

Oregon

Portland
OHSU Knight Cancer Institute
Contact Sarah Clampitt 503-418-8150

Pennsylvania

Philadelphia
University of Pennsylvania/Abramson Cancer Center
Contact Caitlin Orr 215-615-3004

Texas

San Antonio
University of Texas Health Science Center at San Antonio
Contact Molly Doris 210-567-1172

Washington

Seattle
Fred Hutchinson Cancer Center/University of Washington
Contact Chenee Holcomb 206-598-0850

 

Lead Researchers/Study PIs and Affiliation

Heather H. Cheng, MD, PhD University of Washington / Fred Hutchinson Cancer Center;
Daniel W. Lin, MD; University of Washington
patrol@uw.edu

This Study is Open To:

The study is open to people with prostates, who are at least 40 years old AND:

  • Have an known in the following genes: , , , , , , , , , , , or .
  • Do not already have a diagnosis of cancer.
  • Are able to provide written informed consent.
This Study is Not Open To:

People with the following are not eligible:

  • have another cancer treated within the past 12 months (e.g. surgery, radiation, chemotherapy, ) for all cancer types except non melanoma skin cancer.
  • prior participation or plan to participate in a clinical trial intended to prevent cancer for people with genetic mutations linked to risk.
  • Unable or unwilling to complete clinical care and study procedures as indicated by the study requirements.